Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

This Solicitation opportunity from Department Of Defense was posted on June 2, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

PHARM MANUF/DISTR DIV - FSA

Closed
SPE2D2-26-R-0004Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The solicitation for Lisdexamfetamine Dimesylate Capsules, identified by number SPE2D2-26-R-0004, is issued by the Defense Logistics Agency Troop Support under the Department of Defense for the procurement of pharmaceutical products in multiple strengths and pack sizes, including 10 mg through 70 mg capsules in both 90- and 100-count bottles. Offers are due by 7:00 PM ET on July 28, 2026, following Amendment 0002 which extended the original deadline. The contract follows a Lowest Price Technically Acceptable (LPTA) evaluation method where proposals must pass two mandatory technical gates: acceptable ratings for both Technical Requirements and Past Performance, with award going to the offeror meeting these thresholds at the lowest aggregate price. The product must comply with stringent packaging and labeling standards, including the use of non-glass containers with childproof caps, a minimum 100cc cylindrical bottle size with a 5.75-inch circumference, and barcodes adhering to GS1-128 or HIBC standards with grade C or better quality, clearly displaying lot number and expiration date. All products require an FDA-approved NDA or ANDA, precise Country of Origin disclosures for both the final product and active pharmaceutical ingredient under the Trade Agreements Act, and unique eleven-digit NDC codes. Delivery is FOB Destination to DLA and VA Pharmaceutical Prime Vendors, with performance readiness required within 45 days of award and pricing becoming effective 15 days after performance start. Contractors must establish business-to-business agreements with PPV vendors for payment, delivery, and chargeback terms, receiving payment indirectly through these vendors rather than directly from the government, and are prohibited from assigning payment rights. The contract includes cost recovery fees of 0.5 percent, payable via Cashlink ACH or Pay.gov using specific identification codes. Compliance is governed by numerous FAR and DFARS clauses including prohibitions on gratuities, subcontractor sales restrictions, contractor ethics, cybersecurity, and telecommunications equipment restrictions, as well as SAM registration and representation certifications that must be current and submitted electronically. Proposals must be submitted exclusively via the DIBBS system with separate non-price and price volumes containing all required documentation, and inclusion of marketing materials is prohibited. The solicitation may proceed to a Reverse Auction after initial evaluation, and all terms bind the contractor to federal procurement regulations under the NAICS code 3254

General Info

DLA seeks suppliers for Lisdexamfetamine capsules, firm-fixed price, one-year base plus four option years.

Agency

Department Of Defense → MEDICAL SUPPLY CHAIN FSGBView Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

USA

Set-Aside

NONE

Documents

(7)

Amendment 0001 to Solicitation SPE2D226R0004

PDFamendment

Solicitation SPE2D2-26-R-0004 for Commercial Items

PDFrfp

Solicitation SPE2D2-26-R-0004 for Lisdexamfetamine

PDFrfp

Amendment 0002 to Solicitation SPE2D226R0004

PDFamendment

Amendment 0002 to Solicitation SPE2D226R0004

PDFamendment

Solicitation SPE2D2-26-R-0004 for Commercial Items

PDFrfq

Amendment 0001 to Solicitation SPE2D226R0004

PDFamendment

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

4 updates
PhaseClosed
Posted

Presolicitation

Type Changed

Presolicitation → Solicitation

Amendment 1

Contract was updated

Amendment 2

Contract was updated

Amendment 3

Contract was updated

Amendment 4

Contract was updated

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → MEDICAL SUPPLY CHAIN FSGB
Contacts1 person available
OfficeUSA
Organization / Agency
Department Of Defense → MEDICAL SUPPLY CHAIN FSGB
View Agency Profile
Office AddressUSA
Contacts
Courtney Hunter

Full Description

Show more
PHARM MANUF/DISTR DIV - FSA NSN/Part Number: 3RFQ3SEESOW

More opportunities from Department Of Defense → MEDICAL SUPPLY CHAIN FSGB

Same awarding agency

NAICS: 325412
DIBBS
PHARM MANUF/DISTR DIV - FSA
Solicitation # SPE2D2-26-R-0012
Solicitation SPE2D2-26-R-0012 is a requirements contract issued by the Defense Logistics Agency (DLA) Troop Support to establish a national supply source for Febuxostat 40mg and 80mg tablets. The objective is to provide these pharmaceutical products to Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the Pharmaceutical Prime Vendor (PPV) program. The contract consists of a one-year base period with four subsequent one-year options, for a maximum term of five years. Award is based on a lowest price technically acceptable (LPTA) basis, requiring offerors to be technically acceptable and provide the lowest evaluated aggregate price. The awarded contractor must enter into business-to-business agreements with DLA and VA PPV contractors, as payments and invoicing will be handled through these prime vendors rather than directly by the government. Key operational requirements include strict adherence to FDA current Good Manufacturing Practices (cGMP), the provision of FDA-approved products with a Therapeutic Equivalence Code of A, and compliance with the Drug Supply Chain Security Act. Packaging must feature child-proof closures and specific bottle dimensions to ensure compatibility with automated dispensing units. Labeling must meet GS1-128 or HIBCC standards with a quality grade of C or better, including lot numbers and expiration dates. The contractor is also required to register product information with RXNorm, First Data Bank, and Medi-Span.
Pharmaceutical Preparation Manufacturing

POSTED

18 days ago

DEADLINE

in 12 days
View Details
NAICS: 424210
DIBBS
PHARM MANUF/DISTR DIV - FSA
Solicitation # SPE2D2-26-R-0015
Solicitation SPE2D2-26-R-0015 is a request for proposal issued by the Defense Logistics Agency (DLA) Troop Support to establish a national supply source for Progesterone 100MG and 200MG capsules. The contract is designed to support the Pharmaceutical Prime Vendor (PPV) program, serving the Department of Defense, Department of Veterans Affairs, Indian Health Service, and the Bureau of Prisons. The award will be for a one-year base period with four optional extension years, for a maximum term of five years. The procurement is unrestricted but includes considerations for small businesses, HUBZone, service-disabled veteran-owned, and women-owned small businesses. The selected contractor must enter into business-to-business agreements with DLA and VA PPV contractors, as payments will be processed through these prime vendors rather than directly from the government. Key performance requirements include a contract performance date 45 days after award and a price effective date within 60 days of award. Deliveries must be completed within 15 calendar days of order receipt. The contractor is required to adhere to strict FDA current Good Manufacturing Practices (cGMP) and specific packaging and labeling standards, including the use of child-proof closures and GS1-128 or HIBCC compliant bar coding at the unit-of-use level. Evaluation is based on a pass/fail technical and past performance assessment, with the final award granted to the lowest evaluated aggregate price. The contractor must also comply with DFARS 252.204-7018 regarding the prohibition of covered defense telecommunications equipment or services, requiring the disclosure of any such use and the implementation of mitigation actions to prevent future occurrences.
Drugs and Druggists' Sundries Merchant Wholesalers

POSTED

about 2 months ago

DEADLINE

in 6 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS